SenzaGen granted its first patent for GARD potency biomarker test16 Jun 2019
Company can now offer an animal-free test method to quantify the strength of an allergenic effect.
SenzaGen's patent application to protect a biomarker signature that measures how strongly allergenic a substance is has now been granted in Europe. The patent is SenzaGen's first patent in the area of potency classification. The patent's validity extends to 2036.
The technology of SenzaGen's patent is implemented in the company's testing application, which for the first time makes it possible to measure the allergenicity of chemical substances, so-called potency classification, without animal research.
“Getting this patent approved for the European market is commercially interesting, as there is a ban within the EU on the sale of animal-tested cosmetic products. Furthermore, to quantify how strong the allergenic effect is according to CLP/GHS is a requirement in the EU chemical regulation REACH. As the only company in the world, SenzaGen can now offer an animal-free test method for this”, says Anki Malmborg Hager, CEO of SenzaGen.
SenzaGen’s IP strategy is to protect the company’s technology in all geographically important markets. Already granted in Europe, China and Hong Kong, patent applications for GARD skin are currently being processed by the patent authorities in countries where animal testing is prohibited or where a ban is expected to be introduced, including the US, Canada and India. In addition, the patent portfolio includes several ongoing patent applications for GARD potency and other GARD products.
SenzaGen’s GARD product portfolio consists of a set of allergy tests with industry-leading performance and accuracy. The tests are performed on human cells in test tubes (in vitro) in combination with artificial intelligence, and replace animal experiments for the cosmetics, chemical and pharmaceutical industries for their tests on whether chemical substances in products can be allergenic.
Eisai collaborates with University of Dundee on cancer drug discovery
10 Jul 2019
It is hoped that research into PROTACs will lead to new drug discoveries for proteins present in cancer, which are difficult to treat with conventional small molecule inhibitors.Read more
Onyx Scientific makes strategic investment in commercial API licence
10 Jul 2019
Investment fills the growing gap in the market for manufacturers that have the niche capabilities to deliver small-scale commercial API projects.Read more
I Holland to share the science behind tool maintenance
9 Jul 2019
Proper maintenance - rather than replacement - of compression tooling will improve profitability.Read more
Catalent extends global commercial spray drying capabilities in Europe
9 Jul 2019
Company's customers to have immediate access to Niro PSD2 and PSD4 spray driers, which are supported by dedicated clean area facilities for both solvent and aqueous processing of potent or non-potent drug formulations.Read more
Operations commence at Wasdell Group’s EU headquarters
8 Jul 2019
The new facility houses 11 bespoke production suites and temperature controlled high-way warehouses increases Wasdell’s capacity in clinical and commercial packaging, distribution & logistics and QP services.Read more
Porvair Sciences launches first Drosophila ChIP kits
4 Jul 2019
Offers a single optimised Chromatrap kit with unique buffers and components for Drosophila chromatin extraction and ChIP.Read more
Boehringer Ingelheim expands NASH R&D pipeline with new first-in-class compound
3 Jul 2019
Yuhan Corporation to receive up to USD 870 million in upfront and success-based development and commercialization milestones, excluding royalties.Read more
Fresh data on protein interactions in Alzheimer’s disease
2 Jul 2019
Demonstrates the unique ability of diffusional sizing to assess protein binding in-solution and for difficult-to-study systems.Read more
Fujifilm Irvine Scientific to open new cell culture media manufacturing site in Europe
2 Jul 2019
The space will support cGMP manufacturing of animal component-free, dry powder media, liquid media, and downstream bioprocessing liquids.Read more
Novartis bolsters ophthalmic portfolio with acquisition of Xiidra
1 Jul 2019
Xiidra 5% is the first and only prescription treatment approved to treat both signs and symptoms of dry eye by inhibiting inflammation caused by the disease.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation